These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11955850)

  • 1. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation.
    Mitchell LB; Pineda EA; Titus JL; Bartosch PM; Benditt DG
    J Am Coll Cardiol; 2002 Apr; 39(8):1323-8. PubMed ID: 11955850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
    Elliott PM; Sharma S; Varnava A; Poloniecki J; Rowland E; McKenna WJ
    J Am Coll Cardiol; 1999 May; 33(6):1596-601. PubMed ID: 10334430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sudden death in implantable cardioverter-defibrillator recipients: clinical context, arrhythmic events and device responses.
    Pires LA; Lehmann MH; Steinman RT; Baga JJ; Schuger CD
    J Am Coll Cardiol; 1999 Jan; 33(1):24-32. PubMed ID: 9935004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sudden death in recipients of first-generation implantable cardioverter defibrillators: analysis of terminal events. Participating investigators.
    Lehmann MH; Thomas A; Nabih M; Steinman RT; Fromm BS; Shah M; Norsted SW
    J Interv Cardiol; 1994 Oct; 7(5):487-503. PubMed ID: 10155197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
    Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
    Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of implantable cardioverter defibrillators in non VT/VF sudden deaths.
    Thakur RK; Aufderheide TP; Tresch DD; Ghani M
    Pacing Clin Electrophysiol; 1994 Jul; 17(7):1264-6. PubMed ID: 7937232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term outcome after cardioverter-defibrillator implantation in patients with Brugada syndrome].
    Binbin Y; Jingping L; Bing Y; Minglong C; Jiangang Z; Kejiang C; Qijun S
    Zhonghua Xin Xue Guan Bing Za Zhi; 2015 Aug; 43(8):690-4. PubMed ID: 26955725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shock Without Wires: A Look at Subcutaneous Implantable Cardioverter-Defibrillator Compared to Transvenous Implantable Cardioverter-Defibrillator for Ventricular Arrhythmias.
    Raja J; Guice K; Oberoi M; Whitwell S; Asbeutah AA; Russell A; Khouzam RN
    Curr Probl Cardiol; 2022 Sep; 47(9):100927. PubMed ID: 34311985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical course and prognostic relevance of antitachycardia pacing-terminated ventricular tachyarrhythmias in implantable cardioverter-defibrillator patients.
    Kleemann T; Strauss M; Kouraki K; Zahn R
    Europace; 2015 Jul; 17(7):1068-75. PubMed ID: 25687746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
    Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis.
    Varr BC; Zarafshar S; Coakley T; Liedtke M; Lafayette RA; Arai S; Schrier SL; Witteles RM
    Heart Rhythm; 2014 Jan; 11(1):158-62. PubMed ID: 24121001
    [No Abstract]   [Full Text] [Related]  

  • 17. Ventricular tachyarrhythmias in patients receiving an implantable cardioverter-defibrillator for primary versus secondary prophylaxis indications.
    Manuchehry A; Agusala K; Montevecchi M; Kadish A; Passman R
    Pacing Clin Electrophysiol; 2011 May; 34(5):571-6. PubMed ID: 21208242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
    Tompkins CM; Kutyifa V; Arshad A; McNitt S; Polonsky B; Wang PJ; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):862-871. PubMed ID: 25929699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arrhythmia rate distribution and tachyarrhythmia therapy in an ICD population: results from the INTRINSIC RV trial.
    Sullivan RM; Russo AM; Berg KC; Stolen KQ; Seth M; Perschbacher D; Day JD; Olshansky B
    Heart Rhythm; 2012 Mar; 9(3):351-8. PubMed ID: 22016074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.